Gilead Sciences, Inc. $GILD Shares Sold by Eukles Asset Management

Eukles Asset Management trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 90.7% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 1,244 shares of the biopharmaceutical company’s stock after selling 12,172 shares during the period. Eukles Asset Management’s holdings in Gilead Sciences were worth $153,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Massachusetts Financial Services Co. MA lifted its stake in shares of Gilead Sciences by 3,763.8% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock worth $518,368,000 after acquiring an additional 4,113,999 shares during the period. Vanguard Group Inc. increased its stake in shares of Gilead Sciences by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock worth $14,863,487,000 after acquiring an additional 2,113,692 shares during the period. First Trust Advisors LP increased its stake in shares of Gilead Sciences by 154.3% during the third quarter. First Trust Advisors LP now owns 3,089,283 shares of the biopharmaceutical company’s stock worth $342,910,000 after acquiring an additional 1,874,508 shares during the period. Invesco Ltd. raised its holdings in Gilead Sciences by 12.0% during the third quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock worth $1,680,505,000 after purchasing an additional 1,618,453 shares in the last quarter. Finally, Danske Bank A S purchased a new position in Gilead Sciences during the third quarter worth about $133,049,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on GILD shares. Truist Financial reaffirmed a “buy” rating and issued a $157.00 price objective (up from $155.00) on shares of Gilead Sciences in a report on Friday, May 8th. Citigroup increased their target price on Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. UBS Group raised their price target on Gilead Sciences from $145.00 to $155.00 and gave the company a “buy” rating in a report on Monday, January 26th. Deutsche Bank Aktiengesellschaft upped their price objective on Gilead Sciences from $135.00 to $155.00 and gave the stock a “buy” rating in a report on Wednesday, February 11th. Finally, Sanford C. Bernstein reiterated an “outperform” rating and issued a $160.00 price objective on shares of Gilead Sciences in a research report on Wednesday, February 11th. Twenty-five investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $156.93.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $134.36 on Tuesday. The company has a market capitalization of $166.82 billion, a PE ratio of 18.31 and a beta of 0.31. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. Gilead Sciences, Inc. has a 52-week low of $104.46 and a 52-week high of $157.29. The stock has a fifty day simple moving average of $136.05 and a 200-day simple moving average of $133.81.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. During the same period in the previous year, the firm posted $1.81 EPS. The company’s quarterly revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, equities research analysts expect that Gilead Sciences, Inc. will post -0.79 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.69%.

Insider Buying and Selling at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $129.16, for a total value of $1,291,600.00. Following the transaction, the chief executive officer owned 632,567 shares in the company, valued at approximately $81,702,353.72. This trade represents a 1.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $132.27, for a total value of $396,810.00. Following the completion of the transaction, the chief financial officer directly owned 173,191 shares in the company, valued at $22,907,973.57. This represents a 1.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 63,000 shares of company stock worth $8,523,570 in the last 90 days. 0.30% of the stock is owned by company insiders.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead completed its $3.15 billion acquisition of Tubulis GmbH, adding a new antibody-drug conjugate platform that should strengthen its oncology pipeline and broaden growth opportunities. Gilead Sciences (GILD) Acquires Tubulis for $3.15B to Expand Oncology Portfolio
• Positive Sentiment: Gilead received an FDA approval for Hepcludex, the first U.S. treatment for chronic hepatitis delta, while Europe’s CHMP backed Trodelvy for triple-negative breast cancer, reinforcing the company’s near-term commercial and pipeline momentum. GILD Scores FDA Win for HDV Drug, CHMP Backs Trodelvy
• Positive Sentiment: Maxim upgraded Gilead Sciences to Buy, adding to the view that the shares remain attractive at current levels and are supported by dividend income and a solid franchise. Maxim Upgrades Gilead Sciences (GILD) to ‘Buy’
• Positive Sentiment: Brokerage coverage remains supportive overall, with Gilead carrying an average “Moderate Buy” rating, which can help underpin investor sentiment. Gilead Sciences, Inc. (NASDAQ:GILD) Receives Average Rating of “Moderate Buy” from Brokerages
• Neutral Sentiment: Articles discussing stocks trading below estimated fair value are broad market pieces and do not provide a specific company-specific catalyst for Gilead. Three Stocks That May Be Trading Below Their Estimated Value In May 2026
• Neutral Sentiment: Another “top stocks trading below fair value” market roundup is similarly general and not a direct catalyst for GILD. May 2026’s Top Stocks That Could Be Trading Below Estimated Fair Value

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.